Phase I Pharmacokinetic Study of the VEGFR Tyrosine Kinase Inhibitor Vatalanib (PTK787) plus Imatinib and Hydroxyurea for Malignant Glioma

BACKGROUND: We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Reardon, David A., Egorin, Merrill J., Desjardins, Annick, Vredenburgh, James J., Beumer, Jan H., Lagattuta, Theodore F., Gururangan, Sridharan, Herndon, James E., Salvado, August J., Friedman, Henry S.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2691174/
https://ncbi.nlm.nih.gov/pubmed/19248046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24213
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars